Suppr超能文献

阴道内使用米索前列醇用于妊娠晚期宫颈成熟的安全性和有效性

[Safety and efficacy of intravaginal misoprostol for cervical ripening in the third trimester of pregnancy].

作者信息

Wang Z, Li W, Ouyang W

机构信息

Union Hospital, Tongji Medical University Wuhan.

出版信息

Zhonghua Fu Chan Ke Za Zhi. 1997 Jun;32(6):326-8.

PMID:9596908
Abstract

OBJECTIVE

To evaluate the safety and efficacy of intravaginal misoprostol for cervical ripening in late trimester.

METHOD

A randomized, double-blind, placebo-controlled trial was conducted. 85 patients with indication for induction of labor and unfavorable cervices were randomly assigned to receive either intravaginal misoprostol (100 micrograms) or placebo placed in the posterior vaginal fornix at one time. The Bishop score, fetal heart rate monitoring and Doppler blood flow velocity waveforms were measured before and 12 hours after drug insertion. Placenta and decidua were observed histopathologically in some cases. Among 85 patients enrolled, 43 received misoprostol and 42 received placebo.

RESULTS

The mean initial Bishop scores were not significantly different between the two groups, while the mean Bishop score in the misoprostol group was significantly higher than that in the placebo group (4.4 for misoprostol versus 1.0 for placebo, P < 0.01). The prevalence of spontaneous labor within 12 hours after misoprostol insertion (67.4%, 29/43) was significantly higher than that in the placebo group (14.3%, 6/42) (P < 0.01). The average Doppler velocity systolic to diastolic (S/D) ratios of umbilical artery, middle cerebral artery, renal artery were not significantly different before and 12 hours after drug insertion between both groups. There was no significant difference in frequency of abnormal fetal heart rate tracings or fetal distress and in the mean Apgar score between the two groups. Except the presence of vasodilation in villi vessels in the misoprostol group, no significant difference existed between the two groups in the placental and decidual histopathological changes.

CONCLUSION

Intravaginal misoprostol may be an effective and safe cervical ripening agent in late pregnancy.

摘要

目的

评估阴道内使用米索前列醇在孕晚期促宫颈成熟的安全性和有效性。

方法

进行了一项随机、双盲、安慰剂对照试验。85例有引产指征且宫颈条件不佳的患者被随机分配,一次性在阴道后穹窿放置阴道内米索前列醇(100微克)或安慰剂。在用药前及用药后12小时测量 Bishop评分、胎儿心率监测及多普勒血流速度波形。部分病例进行胎盘和蜕膜的组织病理学观察。85例入组患者中,43例接受米索前列醇,42例接受安慰剂。

结果

两组的初始平均 Bishop评分无显著差异,而米索前列醇组的平均 Bishop评分显著高于安慰剂组(米索前列醇组为4.4,安慰剂组为1.0,P<0.01)。米索前列醇用药后12小时内自然分娩的发生率(67.4%,29/43)显著高于安慰剂组(14.3%,6/42)(P<0.01)。两组用药前及用药后12小时脐动脉、大脑中动脉、肾动脉的平均多普勒收缩期与舒张期(S/D)比值无显著差异。两组胎儿心率异常或胎儿窘迫的发生率及平均阿氏评分无显著差异。除米索前列醇组绒毛血管有血管扩张外,两组胎盘和蜕膜的组织病理学变化无显著差异。

结论

阴道内使用米索前列醇可能是孕晚期一种有效且安全的促宫颈成熟药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验